Concert Pharmaceuticals (NASDAQ:CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata. As quoted in the press release: “It is important early on in our development program to identify the safest and most effective … Continued
The post Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial appeared first on Investing News Network.